Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes Featured Article: Jennifer.

Slides:

Advertisements

Similar presentations

The role of glucagon and GLP-1 in the regulation of appetite. Katherine Simpson, Jennifer Parker, Niamh Martin, Ben Field, James Minnion, Mohammad Ghatei.

Advertisements

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

Faculty Disclosure Mikayla Spangler, PharmD, BCPS Dr. Spangler has listed no financial interest/arrangement that would be considered a conflict of interest.

Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 Featured Article: Lydia W. Turner, David Nartey, Randall S. Stafford, Sonal Singh, and G.

Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin Featured Article: Beverley Balkau, Philip D. Home, Maya Vincent,

New Insulin Glargine 300 Units∙mL2-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine.

Six-Week Versus Twelve-Week Antibiotic Therapy for Nonsurgically Treated Diabetic Foot Osteomyelitis: A Multicenter Open-Label Controlled Randomized Study.

Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes Featured Article: Michaela Diamant, Michael A.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.

Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial Featured Article: Ravi Retnakaran, Caroline K.

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.

An Automated Internet Behavioral Weight-Loss Program by Physician Referral: A Randomized Controlled Trial Featured Article: J. Graham Thomas, Tricia M.

Consider this Combo: GLP-1 Receptor Agonists and Basal Insulin Matt Heinsen, PharmD PGY2 Pharmacotherapy Resident Butler University & Community Health.

Journal Club 2009 年 1 月 29 日（木） 8 ： 20 ～ 8 ： 50 B 棟 8 階カンファレンスルーム薬剤部 TTSP 石井英俊.

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.

Ali Ardestani, David Rhoads, Ali Tavakkoli

Antibiotics Versus Conservative Surgery for Treating Diabetic Foot Osteomyelitis: A Randomized Comparative Trial Featured Article: José Luis Lázaro-Martínez,

Obesity is a growing epidemic A disease of enormous proportions >65% adults are overweight >30% adults are obese in US (Ogden et al, 2006) Associated with.

Metabolic Effects of Bariatric Surgery

Randomized Controlled Trial of Intensive Versus Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft Surgery: GLUCOCABG Trial.

Part 2 of 2.  GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular.

Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized,

Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes Featured.

Efficacy and Safety of Canaglifozin, a Sodium- Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes Featured Article:

Relationship of Dopamine Type 2 Receptor Binding Potential With Fasting Neuroendocrine Hormones and Insulin Sensitivity in Human Obesity Featured Article:

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Featured Article: Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra.

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.

Gestational Age and Birth Weight and the Risk of Childhood Type 1 Diabetes: A Population- Based Cohort and Sibling Design Study Featured Article: Ali S.

Leptin Is Associated With Exaggerated Brain Reward and Emotion Responses to Food Images in Adolescent Obesity Featured Article: Ania M. Jastreboff, Cheryl.

Fasting Until Noon Triggers Increased Postprandial Hyperglycemia and Impaired Insulin Response After Lunch and Dinner in Individuals With Type 2 Diabetes:

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.

Intensive Versus Intermediate Glucose Control in Surgical Intensive Care Unit Patients Featured Article: Takehiro Okabayashi, Yasuo Shima,Tatsuaki Sumiyoshi,

Extra-Virgin Olive Oil Reduces Glycemic Response to a High–Glycemic Index Meal in Patients With Type 1 Diabetes: A Randomized Controlled Trial Featured.

Supported by Virtual Poster Hall: Summary Slides Professor Stephan Matthaei Tuesday, September 15 th This Virtual Poster Hall session explores the relationship.

Metabolic GI peptide hormones Ghrelin Insulin Glucagon Insulin Glucagon GIP GLP-1 Insulin Leptin Insulin Adiposity tissue insulin Insulin.

Featured Article: Wayne H.-H. Sheu, Ira Gantz, Menghui Chen, Shailaja Suryawanshi, Arpana Mirza, Barry J. Goldstein, Keith D. Kaufman, and Samuel S. Engel.

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week,

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose- Ranging.

GLP-1 agonists Ian Gallen Consultant Community Diabetologist

Mastery of Medicine in Diabetes Management Video Roundtable

Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes Bernt Johan von Scholten, Tine.

Volume 26, Issue 2, Pages e2 (August 2017)

Can Primary Care Physicians Take the Lead in Combating Obesity?

Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled.

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

James F. List, Jean M. Whaley Kidney International

Obesity and Weight Loss: How Can Cross-Functional Collaboration and Integrated Care Work in Practice?

Volume 26, Issue 2, Pages e2 (August 2017)

Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Predicted and observed BMI levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

1018-NT-β-cell clusters protect mice from STZ-induced diabetes.

The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

The effect of VSG on body weight and body fat in GLP-1r KO mice.

Rapid improvement of glucose tolerance induced by PP

Food intake in response to central infusion of glucose (squares) or insulin (triangles) and in response to successive central infusion of insulin, insulin.

Study protocol. Study protocol. A: Study design. Ten candidates for RYGB were studied in an acute intervention study. All participants underwent four test.

Effect of empagliflozin on efficacy parameters at week 18.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.

Case report: male 63 years old with documented stenosis of the internal cerebral artery, diabetes duration 12 years, and treatment with 22 IU insulin glargine.

Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.

Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Insulin Delivery Systems Atlanta Diabetes Associates

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Intranasal Glucagon Investigators

Presentation transcript:

Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes Featured Article: Jennifer S. ten Kulve, Dick J. Veltman, Liselotte van Bloemendaal, Frederik Barkhof, Madeleine L. Drent, Michaela Diamant, and Richard G. IJzerman Diabetes Care Volume 39: 214–221 February 2016

STUDY OBJECTIVE Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with reduced appetite and body weight This study investigates whether these effects could be mediated by the central nervous system (CNS) ten Kulve J.S. et al. Diabetes Care 2016;39:214–221

STUDY DESIGN AND METHODS Randomized crossover study was performed in obese patients with type 2 diabetes Study consisted of two periods of 12-week treatment with either liraglutide 1.8 mg or insulin glargine Effects of treatment on CNS responses were determined by viewing food pictures in the fasted condition and 30 min after a meal ten Kulve J.S. et al. Diabetes Care 2016;39:214–221

RESULTS Decrease in HbA 1c was larger with liraglutide than insulin glargine Body weight decreased during liraglutide versus insulin glargine Patients treated with liraglutide showed decreased responses to food pictures in insula and putamen Liraglutide enhanced the satiating effect of meal intake on responses in putamen and amygdala Differences between liraglutide and insulin glargine were not observed after 12 weeks ten Kulve J.S. et al. Diabetes Care 2016;39:214–221

CONCLUSIONS Liraglutide decreased CNS activation signiﬁcantly only after short-term treatment ten Kulve J.S. et al. Diabetes Care 2016;39:214–221